SLS BIO (A246250) Stock Overview
Develops diagnostic technologies in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A246250 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
SLS BIO Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,969.00 |
| 52 Week High | ₩4,590.00 |
| 52 Week Low | ₩1,431.00 |
| Beta | 0.76 |
| 1 Month Change | 0% |
| 3 Month Change | 4.51% |
| 1 Year Change | -44.92% |
| 3 Year Change | -46.64% |
| 5 Year Change | -74.18% |
| Change since IPO | -22.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| A246250 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 4.9% |
| 1Y | -44.9% | 10.1% | 112.0% |
Return vs Industry: A246250 underperformed the KR Life Sciences industry which returned 17.9% over the past year.
Return vs Market: A246250 underperformed the KR Market which returned 24% over the past year.
Price Volatility
| A246250 volatility | |
|---|---|
| A246250 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 10.6% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in KR Market | 15.4% |
| 10% least volatile stocks in KR Market | 4.3% |
Stable Share Price: A246250's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: Insufficient data to determine A246250's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Lee Young Tae | www.slabs.co.kr |
SLS BIO Co., Ltd develops diagnostic technologies in South Korea. It offers pharmaceuticals quality control testing services, including pharmaceutical equivalence study, raw materials/finished drugs test, and other analysis testing services; and efficacy evaluation services, such as immune function-based efficacy evaluation and pharmacokinetics and toxicokinetics analysis services. In addition, it provides diagnostic kits comprising rapid allergy test, rapid bovine pregnancy diagnosis, and horse individual forensic kits, as well as nano-bio technologies.
SLS BIO Co., Ltd Fundamentals Summary
| A246250 fundamental statistics | |
|---|---|
| Market cap | ₩26.89b |
| Earnings (TTM) | -₩1.54b |
| Revenue (TTM) | ₩7.29b |
Is A246250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A246250 income statement (TTM) | |
|---|---|
| Revenue | ₩7.29b |
| Cost of Revenue | ₩6.14b |
| Gross Profit | ₩1.15b |
| Other Expenses | ₩2.69b |
| Earnings | -₩1.54b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -112.57 |
| Gross Margin | 15.81% |
| Net Profit Margin | -21.07% |
| Debt/Equity Ratio | 0% |
How did A246250 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/06 13:23 |
| End of Day Share Price | 2025/06/09 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SLS BIO Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.